Disruption of Transforming Growth Factor β Signaling by a Novel Ligand-dependent Mechanism by Fernandez, Tania et al.
 
1247
 
The Journal of Experimental Medicine • Volume 195, Number 10, May 20, 2002 1247–1255
http://www.jem.org/cgi/doi/10.1084/jem.20011521
 
Disruption of Transforming Growth Factor 
 
  
 
Signaling by a 
Novel Ligand-dependent Mechanism
 
Tania Fernandez,
 
1 
 
Stephanie Amoroso,
 
1 
 
Shellyann Sharpe,
 
1
 
Gary M. Jones,
 
2 
 
Valery Bliskovski,
 
2 
 
Alexander Kovalchuk,
 
2
 
Lalage M. Wakeﬁeld,
 
1 
 
Seong-Jin Kim,
 
1 
 
Michael Potter,
 
2
 
and John J. Letterio
 
1
 
1
 
Laboratory of Cell Regulation and Carcinogenesis and 
 
2
 
The Laboratory of Genetics, The National Cancer Institute, 
The National Institutes of Health, Bethesda, MD 20892
 
Abstract
 
Transforming growth factor (TGF)-
 
  
 
is the prototype in a family of secreted proteins that act
in autocrine and paracrine pathways to regulate cell development and function. Normal cells
typically coexpress TGF-
 
 
 
 receptors and one or more isoforms of TGF-
 
 
 
, thus the synthesis
and secretion of TGF-
 
 
 
 as an inactive latent complex is considered an essential step in regula-
ting the activity of this pathway. To determine whether intracellular activation of TGF-
 
 
 
 re-
sults in TGF-
 
 
 
 ligand–receptor interactions within the cell, we studied pristane-induced
plasma cell tumors (PCTs). We now demonstrate that active TGF-
 
 
 
1 in the PCT binds to in-
tracellular TGF-
 
 
 
 type II receptor (T
 
 
 
RII). Disruption of the expression of TGF-
 
 
 
1 by anti-
sense TGF-
 
 
 
1 mRNA restores localization of T
 
 
 
RII at the PCT cell surface, indicating a
ligand-induced impediment in receptor trafficking. We also show that retroviral expression of
a truncated, dominant-negative T
 
 
 
RII (dnT
 
 
 
RII) effectively competes for intracellular bind-
ing of active ligand in the PCT and restores cell surface expression of the endogenous T
 
 
 
RII.
Analysis of TGF-
 
 
 
 receptor–activated Smad2 suggests the intracellular ligand–receptor com-
plex is not capable of signaling. These data are the first to demonstrate the formation of an in-
 
tracellular TGF-
 
 
 
–receptor complex, and define a novel mechanism for modulating the TGF-
 
 
 
signaling pathway.
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Introduction
 
Among the effects of TGF-
 
 
 
, the regulation of cell growth,
cell death, differentiation, and genomic stability appear to
be of particular importance (1, 2). The loss of responsive-
ness to TGF-
 
 
 
 represents a significant step in the process of
carcinogenesis (3), and several mechanisms underlying the
development of TGF-
 
 
 
 resistance have been identified (2).
These mainly involve a disruption in either the expression
or function of components of the TGF-
 
 
 
 signaling path-
way. TGF-
 
 
 
 transduces signals via heteromeric complexes
of the type I TGF-
 
  
 
(T
 
 
 
RI)
 
* 
 
and type II TGF-
 
 
 
 (T
 
 
 
RII)
serine/threonine kinase receptors (4). After ligand binding
to T
 
 
 
RII, T
 
 
 
RI is recruited into the complex and acti-
vated by T
 
 
 
RII-dependent phosphorylation, thereby en-
abling it to transduce signals through downstream media-
tors such as the Smad family of proteins (5).
The TGF-
 
 
 
 ligand–receptor system has rapidly emerged
as an important tumor suppressor pathway that acts to re-
strain cellular proliferation and to regulate differentiation
(1). The first association between resistance to growth inhi-
bition by TGF-
 
 
 
 and lack of T
 
 
 
RII receptor expression
was reported in retinoblastoma cells (6). Such loss of
T
 
 
 
RII expression has since been reported in several types
of human cancer, including small cell cancer of the lung
(7), hepatoma (8), gastric (9), squamous cell (10), esoph-
ageal (11), and breast cancer (12). Known mechanisms un-
derlying receptor down-regulation include mutations asso-
ciated with the microsatellite instability phenotype (13),
mutations of the T
 
 
 
RII gene promoter (14), transcrip-
tional repression by the EWS-FLI1 oncogene (15), and
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RII, type II TGF-
 
 
 
 receptor. 
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DNA methylation of CpG islands in the T
 
 
 
RII promoter
(16). Loss of TGF-
 
 
 
 receptors at the cell surface has also
been described in the absence of gross structural changes,
mutations, or transcriptional repression, which suggests that
alternative pathways of receptor deregulation must exist
 
.
 
The role of the TGF-
 
 
 
 ligands in disease pathogenesis is
more complex. Most tumor cells retain the ability to ex-
press TGF-
 
 
 
 and often secrete an active form of the ligand.
When coupled with a resistance to the inhibitory effects of
TGF-
 
 
 
, overexpression of this ligand by the malignant cell
could confer a growth advantage through the suppression
of immune surveillance (17), promotion of angiogenesis,
and stimulation of stroma (18). This potential for TGF-
 
 
 
 to
exert pro-oncogenic effects in a context in which the tu-
mor cell has an acquired defect in the TGF-
 
 
 
 receptor sys-
tem has been frequently observed in human cancer (19).
The production of active TGF-
 
 
 
 by plasma cell tumors
(PCTs) in mice has been linked to immune dysfunction
(20), including the inhibition of cytotoxic T lymphocytes
(21). Immune suppression has also been linked to plasma
cell production of active TGF-
 
 
 
 in the setting of autoim-
mune disease (22). These studies in the MRL/lpr mouse
not only implicate B cells and plasma cells as an important
source of circulating active TGF-
 
 
 
, but also provide his-
tochemical evidence that suggests the activation of TGF-
 
 
 
occurs within the plasma cell (23).
We have previously demonstrated that all PCTs that de-
velop in pristane-primed mice not only secrete active
TGF-
 
 
 
, but also uniformly lack the ability to bind exoge-
nous TGF-
 
 
 
 at the cell surface (24). In restoring surface
T
 
 
 
RII, either by disrupting expression of TGF-
 
 
 
1 with
antisense mRNA or by competing ligand binding with a
truncated T
 
 
 
RII, we now reveal a novel mechanism
whereby the pathologic production of active, intracellular
TGF-
 
 
 
 impedes receptor localization to the plasma mem-
brane and precludes TGF-
 
 
 
 signaling.
 
Materials and Methods
 
Cell Culture.
 
Plasmacytoma cell lines (MOPC315, BPC4,
TEPC2027, TEPC 1165, and X24) and murine B lymphoma cell
lines (CH31, P388, and 8498) were maintained in routine RPMI
1640 media with 10% fetal bovine serum (Biofluids). Recombi-
nant IL-6 (PeproTech) was added at a concentration of 5 ng/ml
for the maintenance of TEPC 1165. Mv1lu cells were maintained
in DMEM containing 10% fetal bovine serum.
 
Constructs and Retroviral Infections.
 
To generate the TGF-
 
 
 
1
antisense vector, a neomycin-resistant gene containing an internal
ribosomal entry site that forms a fusion RNA with antisense
TGF-
 
 
 
1 RNA was subcloned into the BamHI site of the MFG
vector (25). To produce retrovirus, the ABOSC packaging cell
was transfected with 10 
 
 
 
g of either the sense or antisense plas-
mid and cotransfected with 2.5 
 
 
 
g of pCMV-VSV-G. Retroviral
supernatant was collected at 24 h and applied directly to X24
cells. Stable antisense cell lines were selected using G418 and
characterized by standard Northern blot analysis and ELISA
(TGF-
 
 
 
1 Quantikine; R&D Systems).
To generate the dominant-negative T
 
 
 
RII vector (dnT
 
 
 
RII),
a 567-bp fragment of the human T
 
 
 
RII (nucleotide positions
 
335–911), with a 5
 
  
 
hemagglutinin (HA) tag inserted at bp 405,
was cloned into the BamHI-EcoRI site of pcDNA3 (Invitrogen).
The dnT
 
 
 
RII was transfected into TEPC 1165 and expression
was determined by reverse transcription PCR with a forward
primer specific to the HA tag (TF1: 5
 
  
 
GATGTTCCTGAT-
TATGCTAG 3
 
 
 
), and a reverse primer spanning nucleotides
734–759 of the T
 
 
 
RII cDNA (TF2: 5
 
  
 
CATCAGAGCTA-
CAGGAACACATGAAG 3
 
 
 
) that amplified a 350-bp region.
 
Immunohistochemistry.
 
Immunohistochemical analysis was
performed as previously reported by Caver et al. (23). To dem-
onstrate the presence of active intracellular TGF-
 
 
 
, 4-
 
 
 
m sec-
tions through PCT-containing peritoneal granulomas were fixed
in formalin and embedded in paraffin. Slides were submerged in
Trizma buffer solution (TBS) containing 0.1% Triton X-100
(Sigma-Aldrich) at room temperature for 15 min followed by
TBS for 5 min, methanol for 2 min, and 0.6% (vol/vol) hydro-
gen peroxide in methanol for 30 min. Slides were subsequently
washed at room temperature in methanol for 2 min, TBS for 5
min, and three times in TBS containing 0.1% (wt/vol) BSA for
3 min. After treatment with hyaluronidase (1 mg/ml in 100 mM
sodium acetate, 0.85% [wt/vol] NaCl) for 30 min at 37
 
 
 
C, and
three washes in TBS/0.1% BSA, slides were treated with an avi-
din-biotin block (Vectastain) for 15 min at room temperature,
rinsed in TBS, and then blocked with 1% goat serum in TBS
containing 0.5% BSA for 30 min at room temperature. Slides
were incubated with 50 
 
 
 
g/ml biotinylated anti-TGF
 
 
 
1 (1D11;
R&D Systems) that reacts specifically with active and not latent
TGF-
 
 
 
. The primary antibody was biotinylated with avidin-bi-
otin reagent (Zymed Laboratories) according to the manufac-
turer’s instructions. Slides were washed three times in TBS with
0.1% BSA and exposed to ABC complex (Vector Laboratories)
followed by 0.05% diaminobenzidine and 0.1% hydrogen per-
oxide.
 
Cell Fractionation.
 
Membrane and cytosolic fractions were
prepared according to the methods of Koli et al. (26). In brief,
cells were washed with cold PBS, scraped into fractionation
buffer (20 mM Tris-HCl [pH 7.4], 2 mM EDTA, 25 mM NaF, 1
mM DTT, 2 mM NaM0
 
4
 
, 1 
 
 
 
g/ml aprotinin, and 1 
 
 
 
g/ml leu-
peptin) and sheared by repeatedly passing through a 26-gauge
needle. After centrifugation at 100,000 
 
g
 
 for 60 min, the soluble
fraction (cytosol) was removed and the pellet was resuspended in
fractionation buffer containing 0.8% Triton X-100 for 20 min at
4
 
 
 
C. The membrane fraction was cleared from insoluble material
by centrifugation at 12,000 
 
g
 
 for 15 min. Triton X-100 was
added to the cytosol fraction to yield an 0.8% final concentration.
The cytosol and membrane fractions were resolved on 8% SDS-
PAGE gels (Novex) and immunoblotted with antibody to T
 
 
 
RII
at 1 
 
 
 
g/ml followed by a 1:10,000 dilution of horseradish perox-
idase–conjugated goat anti–rabbit secondary antibody. Blots were
developed with Super Signal (Pierce Chemical Co.).
 
Purification and Immunoblotting of 
 
 
 
-Phosphate–linked ATP-
Sepharose–purified Lysates.
 
T
 
 
 
RII was extracted from plasmacy-
toma cell lysates with  -phosphate–linked ATP-Sepharose
(Upstate Biotechnology), which selects for tyrosine and serine/
threonine kinases. Eluted kinase-active supernatants were re-
solved on 8% SDS-PAGE gels (Novex) and immunoblotted with
1  g/ml of C16 and a 1:10,000 dilution of horseradish peroxi-
dase-conjugated goat anti–rabbit secondary antibody.
In Vitro Kinase Assay. 107 cells were washed in cold PBS and
lysed in radioimmunoprecipitation assay (RIPA buffer). Lysates
were pre-cleared and immunoprecipitated with 2  g/ml of an
anti-T RII (N-terminal; Upstate Biotechnology). Complexes
were captured with 50  l of protein G–Sepharose for 1.5 h,1249 Fernandez et al.
and washed five times with RIPA and once with PAN (150 mM
NaCl and 50 mM Pipes, pH 7.4). 5  Ci of 32P- ATP (3,000
Ci/Mmol; Amersham Pharmacia Biotech) in 50  l of kinase
buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM
MgCl2, 5 mM MnCl2, 1 mM NaF, 1 mM NaVO4, and 1 mM
DTT) was added to antibody-bound protein G beads and incu-
bated at room temperature for 30 min. Beads were washed three
times with RIPA and proteins were eluted in sample buffer, sep-
arated on a 10% SDS-PAGE gel (Novex), and immunoblotted
with an antibody to full-length receptor (H567; Santa Cruz Bio-
technology, Inc.).
Receptor Cross-linking Assay. Analysis of cell surface TGF- 
receptor expression by the cross-linking of 125I–TGF-  was per-
formed as previously described (24). Where specified, murine
PCTs were acid washed in 150 mM NaCl and 0.1% acetic acid
according to a standard protocol for stripping ligand from cell sur-
face receptor, as described by Zwaagstra et al. (27). For in vitro
cross-linking analysis of intracellular receptor, cells were washed
with cold PBS and lysed in 20 mM Tris-HCl (pH 7.4), 2 mM
EDTA, 25 mM NaF, 1 mM DTT, 2 mM NaMo4, and 2 mM
NaVO4 with protease inhibitors. After centrifugation at 100,000 g
for 60 min, the soluble fraction (cytosol) was removed and the
pellet was resuspended in fractionation buffer containing 0.8%
Triton X-100 for 20 min at 4 C. Membrane fraction was clarified
by centrifugation at 12,000 g for 15 min. Triton X-100 was also
added to the cytosol fraction to a final 0.8% concentration. The
cytosolic fraction was incubated for 2.5 h with 125I–TGF-  and
then cross-linked with disuccinimidyl suberate (DSS) (Pierce
Chemical Co.) added to a final concentration of 3 mM for the fi-
nal 30 min. The reaction was quenched by the addition of 50
mM Tris-HCl, pH 7.4. Lysates were immunoprecipitated over-
night with anti-T RII (C16). Immunoprecipitates were captured
by protein A–Sepharose beads, separated on a 4–20% PAGE gra-
dient gel, and exposed to film.
Analysis of Endogenous, Intracellular TGF-  Ligand–Receptor
Complex. 107 cells were washed three times in ice-cold wash
buffer (RPMI 1640, 25 mM Hepes, pH 7.4), resuspended in 1 ml
of the same buffer containing 3 mM DSS, and then incubated for
30 min at 4 C. The reaction was quenched with 50 mM Tris, pH
7.5. Cells were washed three times in cold sucrose buffer (250
mM sucrose, 10 mM Tris, pH 7.4, 1 mM EDTA) and lysed for
30 min at 4 C in RIPA buffer with protease inhibitors (Boeh-
ringer). Lysates were centrifuged at 4 C at 10,000 g in a tabletop
Eppendorf centrifuge (model 5415C). Receptor immunoprecipi-
tation was done overnight at 4 C with 1  g/ml of C16 (Santa
Cruz Biotechnology, Inc.). Sample buffer was added with 2-mer-
captoethanol in case of immunoblotting with H567 (Santa Cruz
Biotechnology, Inc.) and without mercaptoethanol in the case of
1D11 (Genzyme), and MCA797 (Serotec). Precipitates were run
on a 4–20% SDS-PAGE gradient gel and transferred onto polyvi-
nylidene difluoride membranes. Blots were incubated with 1  g/
ml of 1D11 or MCA979 diluted in PBS with 1% BSA or H567
diluted in TBST-milk overnight at 4 C. An additional incubation
was done with a 1:10,000 dilution of either a goat anti–mouse or
donkey anti–rabbit secondary antibodies. Blots were developed
with Super Signal (Pierce Chemical Co.).
Analysis of Smad2. Lysates of cells treated with 2.5 ng TGF-
 1/ml in RPMI medium with 0.5% fetal bovine serum were sep-
arated on 8% Tris-glycine gels (Novex). Immunoblotting was
performed with an anti-phoshoSmad2, rabbit polyclonal antibody
(Upstate Biotechnology), followed by a 1:10,000 dilution of
goat–anti rabbit secondary (Jackson ImmunoResearch Laborato-
ries) and visualized with Super Signal (Pierce Chemical Co.).
Conditioned Media Preparation, Proliferation Assays, and Analysis
of TGF-  Production. The methods for the production of se-
rum-free cell supernatants, measurement of DNA synthesis by
[3H]thymidine, and TGF-  ELISAs and bioassays have been pre-
viously described (24). Quantikine TGF- 1 ELISA kits were
purchased from R&D Systems.
Results and Discussion
PCTs Express Normal T RII. Inactivating mutations in
T RII have been described in human malignancies (28,
29). Therefore, to determine if there were any consistent
mutations that would impair the processing, expression, or
function of this receptor, we sequenced cloned segments of
cDNA from T RII mRNA. The sequencing of cDNAs
from five PCTs (BPC4, two variants of MOPC 315,
TEPC 1165, and X24) and from the spleen of normal
BALB/c and C57BL6 mice, showed no consistent bp dif-
ferences (These sequence data are available from GenBank/
EMBL/DDBJ under accession no. AF406755). Any differ-
ences from the published sequence of T RII (from
NIH3T3 cells) were ascribed to differences in the genetic
strain of the mouse (30).
Pristane-induced Plasmacytomas Express a Functional, Ki-
nase-active T RII. T RII receptor is a constitutively
active serine threonine kinase and autophosphorylates its
intracellular domain (31). To characterize the T RII ex-
pressed in the PCT, whole cell lysates were also incubated
with   -phosphate–linked ATP-Sepharose, which selects
for tyrosine and serine/threonine kinases. In Western anal-
ysis of  –ATP-Sepharose–selected proteins with T RII-
specific antibodies, an  70-kD doublet band of T RII is
recognized in the kinase-enriched extracts of the positive
controls (Fig. 1 A, lanes 1 and 6) and in each of the four
PCTs (Fig. 1 A, lanes 2–5), which suggests that T RII
protein is indeed synthesized by the PCTs. To determine
whether the T RII of the murine PCT has kinase activity,
cells from two representative lines (TEPC 1165 and X24)
were incubated with 5  Ci of 32 ATP. Immunoprecipi-
tates of T RII from lysates labeled with 32 ATP resolved
on an 8% SDS gel demonstrate autophosphorylation of the
70-kD T RII receptor both in control lymphomas (Fig. 1
B, lanes 1 and 2) and in PCTs (Fig. 1 B, lanes 3 and 4).
This suggests that the T RII of the pristane-induced PCT
is capable of autophosphorylation and therefore functional.
TGF -II Receptor Protein Is Absent in Membrane Fraction
but Present in the Cytosol. Because the lack of ligand bind-
ing to surface receptors on the PCT is clearly not a conse-
quence of a transcriptional or translational defect (24), we
chose to investigate whether this defect represents a prob-
lem with localization of T RII in the plasma membrane.
We examined the membrane and cytosolic fractions of the
PCTs for the presence of T RII. Western blotting with an
antibody specific for T RII revealed abundant amounts of
receptor protein in the cytosol (Fig. 1 C, lanes 6–8) but not
in the membrane fractions (Fig. 1 C, lanes 2–4) of several
PCTs. The control cell line CH31 (Fig. 1 C, lanes 1 and 5)
shows presence of T RII both in the membrane and cyto-1250 Ligand-dependent Disruption of TGF-  Signaling
solic fractions. The relative absence of receptor protein in
the membrane fractions of PCTs suggests that a defect in
receptor trafficking underlies the inability to bind ligand at
the surface of the PCT.
125I–TGF-  Does Not Bind to T RII in Lysates of PCT
Cells. The absence of membrane T RII can explain the
inability to bind exogenous TGF-  at the cell surface.
However, it should be possible to demonstrate the binding
of  125I–TGF-  to the cytosolic receptor. Receptor cross-
linking was performed with 125I–TGF-  and cytoplasmic
lysates of TEPC 1165 and X24 to investigate whether the
intracellular pool of T RII would bind exogenous TGF-
 1. Binding of 125I–TGF-  to T RII was observed in ly-
sates of control lymphoma cells (Fig. 2, lanes 1 and 2) but
not of PCT cells (Fig. 2 C, lanes 3 and 4). As expected, im-
munoprecipitation with an antibody specific for T RI did
not reveal the binding of 125I–TGF- 1 to T RI (unpub-
lished data), nor did anti-T RII co-precipitate T RI in this
assay, supporting the model in which heteromers of T RI
and T RII do not form in the presence of ligand until they
are on the plasma membrane (32, 33). These data suggest
that either T RII expressed by PCTs is not available for
ligand binding, or that a unique mechanism is responsible
for the sequestration of T RII within the PCT cell.
Absence of Ligand–T RII Complex on the PCT Cell Sur-
face. It is possible that the lack of 125I–TGF-  binding to
T RII in the PCT cell (24) could occur if receptors are
occupied by secreted, endogenous ligand. We previously
reported the secretion of active TGF-  by multiple PCT
cell lines and now provide immunohistochemical evidence
of active intracellular TGF-  in the PCT. Using the mono-
clonal antibody 1D11 that reacts specifically with active
and not latent TGF- , we evaluated sections through in-
Figure 1. Murine PCTs contain active intracellular T RII. (A) Affin-
ity purification of T RII from whole cell plasmacytoma lysates using
 -phosphate–linked ATP-Sepharose. Products were resolved on an 8%
SDS-PAGE gel and immunoblotted with antibody to full-length T RII.
(B) Autophosphorylation of the 70-kD T RII can be visualized when
 -ATP–labeled cell lysates of control lymphomas (lanes 1 and 2) and
PCT cells (lane 3 and 4) are immunoprecipitated with anti-T RII. (C)
T RII is not detected by Western in membrane fractions of PCTs.
Membrane and cytosolic fractions were prepared from the control CH31
(lanes 1 and 5) and PCT cells (lanes 2–4 and 6–8) according to the methods
described in Koli et al. (26) and as summarized in Materials and Methods. 
Figure 2. Intracellular T RII
of the PCT does not bind exoge-
nous ligand. Chemical cross-link-
ing of 125I–TGF-  to cytoplasmic
extracts from the positive control
CH31 (lanes 1 and 2), followed
by immunoprecipitation with
T RII-specific antibodies re-
veals ligand binding. In contrast,
ligand binding to intracellular re-
ceptors could not be detected in
cytoplasmic extracts of the paren-
tal TEPC 1165 (lanes 3 and 4).
Figure 3. Active TGF-  is present in the PCT. (A) To demonstrate the
presence of active intracellular TGF-  in the murine PCT in vivo, we
prepared 4- m sections through PCT-containing peritoneal granulomas
that had been fixed in formalin and embedded in paraffin. Sections were
processed by standard methods for histochemical analysis, as previously
described (23) and incubated with a biotinylated monoclonal antibody
(1D11) that reacts specifically with active and not latent TGF- . (B) To
demonstrate specificity, control sections were incubated with antibody
that had been pre-blocked by incubation with recombinant TGF- 1.
Arrowheads indicate plasma cells. (C) A ligand–receptor complex cannot
be detected at the PCT cell surface. To strip receptor-bound ligand,
whole cells were acid washed followed by incubation with 125I–TGF- 
for detection of surface T RII. There is no evidence of T RII by recep-
tor–ligand affinity labeling in PCTs X24 (lane 2) or 1165 (unpublished
data), either before or after acid wash (X24 acid washed, lane 3). Transient
exposure of whole cells to low pH does not destroy ligand binding capac-
ity of cell surface receptor as shown with the control cell line (unwashed
control, lanes 4 and 5; acid washed control, lane 6). The presence or ab-
sence of unlabeled TGF-  is indicated by   or  , respectively.1251 Fernandez et al.
flammatory granulomas for pristane-primed mice (Fig. 3
A). The specificity of the strong immunohistochemical
staining in plasma cells was demonstrated by pre-blocking
1D11 with recombinant TGF- 1 (Fig. 3 B). Although
Western analysis of membrane fractions indicates a true ab-
sence of T RII at the PCT surface, we wanted to clearly
exclude the possibility that the lack of 125I–TGF- 1 bind-
ing on whole PCT cells (Fig. 3 C, lane 2) is secondary to
receptor occupancy at the cell surface by the active, endog-
enous ligand. We performed an acid wash on whole PCT
cells, a technique that effectively strips ligand from cell sur-
face receptors and allows for subsequent binding with 125I–
TGF- 1 (16). The lack of binding of 125I–TGF- 1 after
the acid wash of both X24 (Fig. 3 C, lane 3) and TEPC
1165 (unpublished data) confirms the true absence of cell
surface localization of receptor. Cell membranes are not af-
fected by transient exposure to low pH and 90–95% of
TGF-  receptor–bound ligand is removed at low pH with-
out affecting subsequent binding capacity (26). With a con-
trol-line cell line (Fig. 3 C, lane 4) we were also able to
show that the acid wash of cells does not destroy ligand
binding capacity of the receptor.
Production of Autocrine, Active TGF- 1 Precludes the Trans-
location of T RII to the Plasma Membrane in the Murine Pris-
tane–induced PCT. To demonstrate the role of autocrine
TGF- 1 in this PCT phenotype, we examined the effects
of blocking endogenous TGF- 1 production through ret-
roviral expression of antisense TGF- 1 (Fig. 4, A and B).
Antisense expression led to a 10-fold reduction of secreted
TGF- 1 as determined by both ELISA and in a bioassay
that evaluates the growth of the TGF- 1–sensitive Mv1Lu
cell line in media conditioned by the PCT (120 pg/ml in
sense control vs. 12.4 pg/ml in antisense line). Expression
of sense has no effect on the pattern of ligand binding at
the cell surface (Fig. 4 B, lane 5). However, the localiza-
tion of T RII at the cell surface is restored by the expres-
sion of antisense TGF- 1, as demonstrated by the binding
of  125I–TGF- 1 to T RII and T RI on the antisense
X24 PCT cells (Fig. 4 B, lane 3). The cross-linking pat-
tern on antisense X24 is competed by excess unlabeled
TGF- 1 (Fig. 4 B, lane 4) and is similar to that of the con-
trol B cell lymphoma CH31 (Fig. 4 B, lanes 1 and 2). The
ability to detect cell surface T RII in antisense X24 and
not in cells expressing a control sense vector suggests that
the effect is a direct consequence of blocking ligand pro-
duction in the PCT.
The data presented so far support a hypothesis in which
the formation of active TGF- 1 within the PCT cell pro-
motes direct intracellular interaction of ligand with T RII,
effectively trapping the receptor and preventing trafficking
to the plasma membrane. If true, the restoration of cell sur-
face localization might occur when the receptor is in rela-
tive excess of available ligand. To test this hypothesis, we
infected a PCT line (TEPC 1165) with a retroviral vector
expressing a dominant-negative version of the TGF-  type
II receptor, dnT RII, which lacks the kinase domain but
has an intact extracellular binding domain and a transmem-
brane domain (34). Thus, the receptor is capable of binding
ligand but is not capable of initiating signaling. We evalu-
ated this line (1165dnRII) for the capacity to bind 125I–
TGF- 1 (Fig. 4 D). The parental cell line TEPC 1165
(Fig. 4 D, lanes 1 and 2) consistently lack the ability to bind
exogenous 125I–TGF- 1. However, the incubation of the
dnT RII-expressing 1165dnRII cells with 125I–TGF- 1
revealed ligand binding to endogenous receptor at the cell
surface (immunoprecipitation of the receptor–ligand com-
plex was performed with an antibody recognizing the
C-terminus of wild-type T RII, thereby distinguishing
the endogenous receptor from the dnT RII; Fig. 4 D, lanes
3 and 4). The ability of the dnT RII to act as a decoy for
endogenous TGF-  is also demonstrated by the ability of
125I–TGF- 1 to bind to T RII in cytoplasmic extracts of
the 1165dnT RII cells (Fig. 4 D, lane 7). These results in-
dicate that the lack of binding of 125I–TGF- 1 to the intra-
Figure 4. Restoration of cell surface expression of T RII. (A and B)
TGF- 1 anti-sense expression and disruption of TGF-  production re-
stores the surface expression of TGF-  receptors (A, top). Northern anal-
ysis of sense and antisense TGF- 1 transfected cell lines with a 32P-labeled
cDNA probe for neomycin (part of the bicistronic message) confirms the
expression of sense and antisense TGF- 1 mRNA (A, bottom). Corre-
sponding ethidium bromide–stained gel. (B) Ligand affinity cross-linking
studies with 125I–TGF-  show a normal receptor complex in the control
CH31 (lane 1), competed by unlabeled TGF-  (lane 2). The restoration
of the cell surface expression of T RII is obtained on transduction of the
parental X24 with the antisense TGF- 1 (antisense X24, lanes 3 and 4).
The binding and chemical cross-linking of 100 pM 125I–TGF-  to
T RII is competed by a 100-fold excess (1 nM) of unlabeled TGF- 1
and is indicated by  . (C and D) Transfection with a truncated T RII
restores surface localization of endogenous T RII (C, top). Hybridization
with a 32P-labeled cDNA neo probe demonstrates the expression of the
dominant-negative T RII mRNA in the PCT 1165 (C, bottom). Ethid-
ium bromide–stained gel of a 375-bp amplimer specific to the HA-tagged
T RII. (D) Chemical cross-linking studies demonstrate the restoration of
endogenous T RII on the cell surface after transduction with the domi-
nant-negative T RII (1165dnRII). In vitro cross-linking of cytosolic
fraction from 1165dnRII demonstrate the presence of free endogenous
T RII that is now available for binding to 125I–TGF-  (lane 7).1252 Ligand-dependent Disruption of TGF-  Signaling
cellular T RII in the parental 1165 (Fig. 2, lanes 3 and 4) is
a consequence of receptor binding to active intracellular
TGF- . When endogenous active TGF-  is sequestered
by the dnT RII in the PCT, there is a pool of endogenous
T RII that then becomes available for binding with exog-
enous ligand (Fig. 4 D, lane 7). Collectively, these data
support the conclusion that autocrine, active intracellular
TGF- 1 blocks the translocation of T RII to the plasma
membrane in the pristane-induced PCT.
Intracellular TGF-  Ligand–Receptor Complexes Are Present
in the Murine Pristane–induced PCT. To directly demon-
strate the existence of an intracellular ligand–T RII com-
plex in the PCT, we performed an “intracellular” cross-
linking assay by exposing intact PCT cells to the permeable
membrane cross-linking reagent, DSS. Unlike traditional
TGF-  receptor cross-linking studies that stabilize the inter-
action of cell surface receptor with 125I–TGF- 1, this exper-
iment relies on the presence of active, endogenous TGF- 1
to cross-link with intracellular T RII. Cross-linked PCT
lysates were immunoprecipitated with a T RII-specific an-
tibody and immunoblotted with either of two distinct mono-
clonal antibodies specific for TGF- 1, or with a polyclonal
antibody raised against the full-length type II receptor. Both
anti–TGF- 1 antibodies clearly detected the existence of an
identical intracellular ligand–receptor complex (Fig. 5 A,
lanes 1 and 4) that was blocked by the pre-incubation of pri-
mary antibody with recombinant TGF- 1, and was not de-
tected by incubation with the secondary antibody alone
(unpublished data). The same complex was also present
when immunoprecipitates were assayed by Western blotting
with an antibody raised against the full-length T RII (Fig. 5
A, lane 5). Because latent TGF-  does not bind T RII, the
demonstration of an intracellular ligand–receptor complex
provides clear evidence that TGF-  is being activated intra-
cellularly and is capable of binding T RII.
The Intracellular TGF-  Ligand–Receptor Complexes Do
Not Signal through Smad2. The presence of an intracellular
ligand–receptor complex raises an important question re-
garding the potential for signaling to occur in an “intra-
crine” fashion, outside the context of the plasma membrane.
To address this question we looked for the presence of the
receptor-activated phosphorylated Smad2 in lysates of both
the parental PCTs and in the antisense and dnT RII-
expressing PCT cell lines (Fig. 5, C and D). No phosphory-
lated Smad2 was detected after the addition of exogenous
ligand to the parental cell lines (Fig. 5, C and D), despite
the fact that both X24 (unpublished data) and TEPC 1165
contain detectable levels of Smad2 protein. This suggests
that the intracellular ligand–receptor complex is incapable
of activating Smad2. More importantly, exogenous ligand
could induce the phosphorylation of Smad2 not only in the
control lymphoma (CH31; Fig. 5 B, top), but also in both
the TGF- 1 antisense and dnT RII-expressing PCT cell
lines, in which we have restored receptor expression at the
cell surface (Fig. 5, C and D).
Figure 5. An intracellular TGF- –T RII complex. (A) Lysates of
DSS-treated whole cells were immunoprecipitated with the anti-T RII
antibody (C16) followed by Western analysis with either antibodies to
TGF- 1 (1D11, lanes 1–3, or MCA797, lane 4) or full-length T RII
(H567, lane 5). Each primary antibody detected the identical intracellular
ligand–receptor complexes with recombinant TGF- 1 loaded as a con-
trol (500 ng, lane 2, and 50 ng, lane 3). (B) An  58-kD phosphorylated
Smad2 band was induced by TGF-  treatment of the control lymphoma,
CH31. (C) TGF- –induced phosphorylation of Smad2 was detected in
the PCT X24 containing the antisense expression vector (lanes 3 and 4),
but not in the sense control line (lanes 1 and 2). Phosphorylation of the
mink lung epithelial cell line (Mv1Lu) is shown as a positive control
(lanes 5 and 6). (D) Similarly, TGF- –induced phosphorylation of Smad2
was detected in the PCT 1165 containing the dnT RII expression vector
(1165dn, bottom). The result demonstrates the ability of TGF-  to
initiate signaling once the endogenous receptor is localized to the
plasma membrane.
Figure 6. A model for the sequestration
of T RII inside the cell by active endoge-
nous TGF- 1. TGF-  is typically secreted
in a biologically latent form and therefore
cannot bind to its cognate receptor,
T RII. (A) In a normal cell, the activation
of TGF- 1 occurs outside the cell where it
can bind cell surface T RII. (B) In our
plasmacytoma model, TGF- 1 is activated
within the cell by a currently unknown
mechanism and can readily bind T RII,
which consequently contributes to the ob-
served loss of TGF-  receptor expression at
the cell surface.1253 Fernandez et al.
It is worth noting that our use of the truncated dnT RII
has clearly given a result that might not be predicted based
on conventional studies in which dominant-negative re-
ceptors have routinely been applied. Such dominant-nega-
tive constructs have invariably been expressed in cells that
have an intact TGF-  signaling pathway. More impor-
tantly, the dnT RII has never been introduced into a cell
that spontaneously produces large amounts of active TGF- 
or contains an intracellular pool of active TGF- , such as
that present within the PCT cell. However, the fact that
one can induce phosphorylated Smad2 in a cell expressing
the dnT RII is not without precedent, as the expression of
a similar dnT RII in the Mv1Lu cell line blocks growth
inhibition in response to TGF- , but not the Smad-depen-
dent induction of fibronectin or the plasminogen activator
inhibitor (35). Regardless, it is clear that the endogenous
T RII synthesized by the PCT is capable of transducing a
signal when localized in the plasma membrane.
It is also important to note that even upon the restora-
tion of the endogenous receptor to the cell surface we were
unable to restore sensitivity to TGF- –mediated growth
inhibition and apoptosis (unpublished data) in either the
antisense X24 line or the 1165dn line. It has recently been
demonstrated that a similar defect in the membrane local-
ization of TGF-  receptors correlates with insensitivity to
the growth inhibitory effects of TGF-  in human mam-
mary epithelial tumors (36). However, this may not be the
primary or principal defect underlying TGF-  resistance,
especially in the PCT where deregulated expression of
c-myc is invariant (37). As the repression of c-myc is critical
for TGF- –induced growth arrest (38), it is possible that
our inability to couple Smad2 phosphorylation with either
growth inhibition or apoptosis in the antisense X24 and
1165dn lines merely reflects an inability to suppress the ex-
pression of c-myc.
In contrast to the majority of growth factors, TGF-  is
normally synthesized and secreted in a biologically latent
form such that it is unable to bind to its cognate receptor,
nor elicit a biological response (39). It is possible that ge-
netic polymorphisms in the TGF-  ligands may result in
the altered production and activation of TGF- . Variants
leading to increased circulating TGF-  have been de-
scribed (40, 41) as well as domain-specific mutations of the
TGF- 1 LAP that potentially result in the formation of a
constitutively active TGF- 1 (42). We have sequenced the
entire coding region for TGF- 1 in two PCTs (MOPC
315 and X24) and found no mutations. Another mecha-
nism that might lead to the aberrant production of active
TGF-  involves the increased production of proteases with
the capacity to cleave the latent precursor. These include
furin-like proteases (43) and matrix metalloproteinases (44,
45). In human myeloma there is significant production of
matrix metalloproteinase (MMP)-9, MMP-2, and MMP-1
(46). So far there are no data regarding such protease activ-
ity in murine PCTs. This remains an area for future investi-
gation. In this report, we provide the first evidence that the
production of active TGF-  within a cell can disrupt auto-
crine TGF-  signaling via the formation of non-productive
intracellular ligand–receptor complexes. In this model, an
intracellular sequestration of T RII by active TGF- 
ligand prevents the receptor from trafficking to the cell sur-
face (Fig. 6). The data support the hypothesis that this
novel mechanism underlies the consistent absence of TGF- 
receptors on the surface of the pristane-induced PCT.
A role for intracellular ligand–receptor interactions in ac-
quired defects in the membrane localization of growth fac-
tor receptors has been previously demonstrated in cells
transformed by the viral oncoprotein v-sis (47, 48). In these
studies, the loss of platelet-derived growth factor receptor
at the cell surface was linked to internal activation of the
receptor by the v-sis gene product. However, although in-
tracellular autocrine loops have been described for v-sis and
for other cytokines (49, 50), our data suggest that intracel-
lular TGF-  ligand–receptor complexes are not capable of
initiating signaling, at least through Smad2. This may be
due to differences in the trafficking of T RI and T RII
(33), such that ligand-bound T RII may not be able to re-
cruit T RI unless both are present at the cell surface. Al-
ternatively, it may reflect the inability of ligand-bound re-
ceptor complexes to recruit cell surface adaptor proteins
such as Smad anchor for receptor activation, which are
required for the phosphorylation of Smad2 (51). Studies
focused on mechanisms of activation of the ligand in the
pristane-induced PCT and the endocytic fate of ligand–
receptor complexes are currently under investigation. In
conclusion, these data not only support the concept that la-
tency is a key step in regulating the TGF-  ligands, but also
demonstrate how the activation of TGF-  within a cell can
impact the TGF-  receptor expression, and therefore im-
pact the responsiveness to both autocrine and paracrine
sources of the cytokine.
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